Do ESR1-related mutations generate neoantigens in hormone-receptor-positive HER2-negative metastatic breast cancer?

被引：0
|
作者：
Lopez, M. [1 ]
Spehner, L. [1 ]
Ramseyer, M. [2 ]
Bouard, A. [2 ]
Dobi, E. [1 ]
Curtit, E. [1 ]
Borg, C. [1 ]
Mansi, L. [1 ]
机构：
[1] Hop Jean Minjoz, CHRU Besancon, Team Therapeut Immunomol Canc, Besancon, France
[2] Doubs, UMR1098, Besancon, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [21] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [22] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [23] OUR TREATMENT STRATEGY FOR PATIENTS WITH HORMONE-RECEPTOR-POSITIVE, HER2-POSITIVE METASTATIC BREAST CANCER
    Tanaka, Haruo
    Umeda, Shuyo
    Murakami, Souichiro
    Ishikawa, Mikimasa
    Tanaka, Kimiharu
    Uchiyama, Akihiko
    BREAST, 2015, 24 : S51 - S51
  • [24] Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
    Falato, Claudette
    Schettini, Francesco
    Pascual, Tomas
    Braso-Maristany, Fara
    Prat, Aleix
    CANCER TREATMENT REVIEWS, 2023, 112
  • [25] Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
    Abdelmaksoud, Bader A.
    Toam, Mostafa M.
    Fayed, Alaa A.
    BREAST CANCER MANAGEMENT, 2019, 8 (03)
  • [26] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [27] Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer
    Uratani, Lucas Fernando
    Bermejo, Francesco Sansone
    Hashizume, Pedro HenriqueShimiti
    Bonadio, Renata Colombo
    Testa, Laura
    CANCER RESEARCH, 2021, 81 (04)
  • [28] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
    Schwartzberg, Lee S.
    Kiedrowski, Lesli A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [29] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [30] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
12345